Fujian Cosunter Pharmaceutical Co., Ltd.

SZSE:300436 Stock Report

Market Cap: CN¥4.3b

Fujian Cosunter Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Fujian Cosunter Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Does Fujian Cosunter Pharmaceutical (SZSE:300436) Have A Healthy Balance Sheet?

Sep 30
Does Fujian Cosunter Pharmaceutical (SZSE:300436) Have A Healthy Balance Sheet?

Optimistic Investors Push Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shares Up 27% But Growth Is Lacking

Sep 30
Optimistic Investors Push Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shares Up 27% But Growth Is Lacking

Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares Climb 34% But Its Business Is Yet to Catch Up

Aug 12
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares Climb 34% But Its Business Is Yet to Catch Up

Some Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shareholders Look For Exit As Shares Take 28% Pounding

Apr 16
Some Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shareholders Look For Exit As Shares Take 28% Pounding

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fujian Cosunter Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300436 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024469-223-70-29N/A
6/30/2024463-227-120-43N/A
3/31/2024444-303-194-67N/A
12/31/2023423-349-376-175N/A
9/30/2023368-252-451-205N/A
6/30/2023371-258-450-237N/A
3/31/2023377-182-443-219N/A
12/31/2022386-127-316-120N/A
9/30/2022397-86-305-87N/A
6/30/2022390-44-300-42N/A
3/31/2022372-46-247-40N/A
1/1/2022370-35-192-18N/A
9/30/2021369-21-138-4N/A
6/30/2021369-14-98-2N/A
3/31/202138015-6612N/A
12/31/202036815-3916N/A
9/30/202036312-3122N/A
6/30/202037311-2335N/A
3/31/20203895-2634N/A
12/31/201941511-3434N/A
9/30/201943924-5245N/A
6/30/201945523-13019N/A
3/31/201942412-13222N/A
12/31/201840216-21811N/A
9/30/201835910-2021N/A
6/30/201830811N/A18N/A
3/31/201830125N/A49N/A
12/31/201729634N/A71N/A
9/30/201730837N/A76N/A
6/30/201731453N/A93N/A
3/31/201731459N/A73N/A
12/31/201631366N/A74N/A
9/30/201630980N/A89N/A
6/30/201631492N/A87N/A
3/31/2016319104N/A103N/A
12/31/2015309103N/A112N/A
9/30/2015297101N/A107N/A
6/30/201528395N/A115N/A
3/31/201526891N/A115N/A
12/31/201425484N/A107N/A
12/31/201317857N/A66N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300436's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 300436's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300436's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300436's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300436's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300436's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y